Artificial Intelligence

Shutterstock posts record 2025 revenue on AI data growth, but a steep Q4 loss and merger costs reveal deep challenges in its core content business.

eToro reports a record $868M in 2025 net contribution and adds $100M to its buyback, betting on AI and its super-app vision despite a Q4 crypto lull.

As Xtract One readies its Q2 results, investors eye its booming backlog against a backdrop of rising competition and ethical questions in AI security.

Ascend Elements' award to TDK Ventures reveals a new VC model, where hands-on partnership is key to building a secure, circular battery supply chain.

Digital engineering firm Simform invests $3M to scale its Microsoft AI practice, aiming to capture market share with proprietary IP and a co-sell strategy.

Tech giant Sony secures access to crucial 5G, Wi-Fi, and video patents, renewing a long-standing agreement with R&D powerhouse InterDigital.

Fresh off a $1.1B IPO and a #1 GreenTech ranking, BETA Technologies faces investors to prove its electric aviation vision is commercially viable.

Now debt-free with $14M in cash, Castellum is leveraging major Navy contracts to fuel its next phase of expansion through acquisitions and innovation.

Cyclerion's novel therapy for treatment-resistant depression, using EEG-guided anesthesia, gains key FDA support and a top-tier advisory board.

With a key depression drug nearing Phase 3 and more data imminent, AtaiBeckley is set to make its case to Wall Street at three major March conferences.

How did a Tennessee 3PL achieve 18x shipment growth? A deep dive into the unified tech platform and AI strategy that’s rewriting the rules of freight.

With a massive dataset from $6.2B in prior authorizations, SamaCare's AI is speeding up access to critical drugs, but raises questions about market power.

Citing 'prolonged underperformance,' activist investor Starboard Value seeks to replace Tripadvisor's board, igniting a battle for control.

As Pasithea Therapeutics heads to a key investor conference, all eyes are on its lead drug, PAS-004, and its potential to treat rare and complex diseases.

A new therapy for a rare brain cancer is one step closer to patients after the FDA accepted tirabrutinib for accelerated review, offering hope where few options exist.

A new managed service uses AI to fight advanced cyber threats, offering unified protection and addressing Canadian data sovereignty for North American firms.

Landmark Phase 3 trial results show psilocybin offers rapid, lasting relief for severe depression, pushing psychedelic medicine closer to the mainstream.

With 13,000 attendees and a bold expansion to Ras Al Khaimah, AIBC Eurasia 2026 highlights a major shift of tech's center of power to the East.

Allocate's 350% asset growth signals a major shift as wealth advisors embrace private markets. Discover how its AI-powered platform is making it possible.

A new health tech company has assembled a star-studded scientific board to back its AI-powered dementia prevention app. But can it deliver on its promise?